Biotech Values

[DewDiligence]

Erbitux compendium listing for H&N cancer?

I’ve heard through the grapevine that Erbitux for the treatment of head-and-neck cancer may have been adopted by one of the two industry–standard compendia—published by United States Pharmacopeia (USP) and American Hospital Formulary Service (AHFS)—that guide off-label drug reimbursement.

Assuming for the sake of discussion that the above is true, I estimate that this action will add $20-40M in annualized U.S. Erbitux sales as soon as CMS (Center for Medicare and Medicaid Services) and private insurers act on it.